Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies
Fludarabine, a nucleoside analog, is commonly used to treat lymphoid malignancies. While the optimal number of cycles of fludarabine per treatment course is not known, common strategies include treatment for 6 cycles or 2-3 cycles past best or complete response. This study is a retrospective revie...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1810 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850215666792005632 |
|---|---|
| author | Donald Pasquale |
| author_facet | Donald Pasquale |
| author_sort | Donald Pasquale |
| collection | DOAJ |
| description | Fludarabine, a nucleoside analog, is commonly used to treat lymphoid malignancies. While the optimal number of cycles of fludarabine per treatment course is not known, common strategies include treatment for 6 cycles or 2-3 cycles past best or complete response. This study is a retrospective review of outcomes in patients with low grade lymphoproliferative disorders treated with fludarabine at our institution who received a limited number of cycles of fludarabine per treatment course based on individual response. A total of 26 patients were treated with 105 cycles of fludarabine in 43 treatment courses. Fludarabine was used as a single agent in 22 treatment courses (51%). Mean (± SD) number of fludarabine cycles administered for the first treatment course to all 26 patients was 2.4 ± 1.5 cycles. Median time to next required therapy was 19.4 months. Subsequent fludarabine treatment cycles resulted in continued sensitivity to therapy but responses were of shorter duration. Kaplan-Meier estimated median overall survival was 122 months. A treatment strategy for low grade lymphoproliferative disorders which utilizes an individualized approach yields fewer number of cycles of fludarabine per treatment course with survival that compares very favorably with historical controls. |
| format | Article |
| id | doaj-art-9db0c658f2354a789d708d75cee6db75 |
| institution | OA Journals |
| issn | 2035-3006 |
| language | English |
| publishDate | 2014-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-9db0c658f2354a789d708d75cee6db752025-08-20T02:08:32ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011Lower Number of Fludarabine Cycles in Patients with Lymphoid MalignanciesDonald Pasquale0Stratton VA Medical CenterFludarabine, a nucleoside analog, is commonly used to treat lymphoid malignancies. While the optimal number of cycles of fludarabine per treatment course is not known, common strategies include treatment for 6 cycles or 2-3 cycles past best or complete response. This study is a retrospective review of outcomes in patients with low grade lymphoproliferative disorders treated with fludarabine at our institution who received a limited number of cycles of fludarabine per treatment course based on individual response. A total of 26 patients were treated with 105 cycles of fludarabine in 43 treatment courses. Fludarabine was used as a single agent in 22 treatment courses (51%). Mean (± SD) number of fludarabine cycles administered for the first treatment course to all 26 patients was 2.4 ± 1.5 cycles. Median time to next required therapy was 19.4 months. Subsequent fludarabine treatment cycles resulted in continued sensitivity to therapy but responses were of shorter duration. Kaplan-Meier estimated median overall survival was 122 months. A treatment strategy for low grade lymphoproliferative disorders which utilizes an individualized approach yields fewer number of cycles of fludarabine per treatment course with survival that compares very favorably with historical controls.https://mjhid.org/index.php/mjhid/article/view/1810FludarabineLymphoproliferative DisordersLymphomaChronic Lymphocytic LeukemiaInfections |
| spellingShingle | Donald Pasquale Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies Mediterranean Journal of Hematology and Infectious Diseases Fludarabine Lymphoproliferative Disorders Lymphoma Chronic Lymphocytic Leukemia Infections |
| title | Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies |
| title_full | Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies |
| title_fullStr | Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies |
| title_full_unstemmed | Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies |
| title_short | Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies |
| title_sort | lower number of fludarabine cycles in patients with lymphoid malignancies |
| topic | Fludarabine Lymphoproliferative Disorders Lymphoma Chronic Lymphocytic Leukemia Infections |
| url | https://mjhid.org/index.php/mjhid/article/view/1810 |
| work_keys_str_mv | AT donaldpasquale lowernumberoffludarabinecyclesinpatientswithlymphoidmalignancies |